Beruflich Dokumente
Kultur Dokumente
INFECTIOUS DISEASES
JOHN A. MOLINARI, PHD
MICHAEL GLICK, DMD
BACTERIAL INFECTIONS
Tuberculosis
Legionella
PROTOZOAL INFECTION:
CRYPTOSPORIDIUM
Microbial Characteristics
Epidemiology and Transmission
Clinical Syndrome
Treatment and Control
VIRAL INFECTIONS
Hepatitis C Virus
HIV Infection
525
526
Principles of Medicine
1954
79,775
1967
45,647
1970
37,137
1975
33,989
1980
27,749
1985
22,201
1986
22,768
BACTERIAL INFECTIONS
1990
25,701
1992
26,673
Tuberculosis
1993
25,313
1994
24,361
1995
22,860
1996
21,337
1997
19,851
1998
18,361
1999
16,607
2000
12,942
CDC. Reported tuberculosis in the United States, 2000. Surveillance Reports; 2001.
the 1985 figure. This trend continued until the peak year of
1992 (26,673 cases). With the development and institution of
appropriate infection control policies and procedures aimed at
minimizing airborne spread of M. tuberculosis, continued
decrease in new TB cases has been noted in each subsequent
year.11,12
ETIOLOGY AND PATHOGENESIS
The genus Mycobacterium contains a variety of species, ranging from human pathogens to relatively harmless organisms.
As the major cause of TB, a chronic communicable disease, M.
tuberculosis is by far the most historically prominent member
of this group of bacteria. In addition to their very slow growth
on special enriched media, these aerobic slender rods are characterized by their acid-fast staining feature. The unusually
high lipid content of the cell wall confers the organisms with
an ability to strongly retain a red dye (carbolfuchsin) after
treatment with an acid-alcohol solution. This unique structure also allows the bacteria to survive outside a hosts body,
suspended in airborne microdroplet nuclei for extended periods of time.
Contrary to a perception believed through the ages, M.
tuberculosis is not a highly contagious bacterium. It does not
synthesize potent exotoxins or extracellular enzymes, and it is
not surrounded by an antiphagocytic capsule. Onset of infection appears to be related to the ability of tubercle bacilli to
multiply within host cells and tissues while at the same time
resisting host defenses. Infection with M. tuberculosis typically
requires prolonged close contact of a susceptible host with an
infectious source. The closeness of the contact with
aerosolized bacilli and the degree of infectivity of the
Infectious Diseases
FIGURE 20-1 Sequence of infection from a Mycobaterium tuberculosisladen microdroplet in a susceptible person.
527
FIGURE 20-3 Positive 48-hour skin test following purified protein derivative intradermal challenge of a person with primary asymptomatic tuberculosis. No evidence of clinical disease was present, and the patient
remained asymptomatic following a prolonged course of isoniazid
chemotherapy.
528
Principles of Medicine
(Figure 20-5) and in tooth extraction sites, and may even affect
the tongue and floor of the mouth (Figure 20-6).
When reviewing this information, it becomes apparent
that progression of infection with tubercle bacilli to more
severe disseminated stages occurs in the absence of adequate
cellular immunity to infection. Thus, the ability of an
infected individual to develop a dual immune response
against M. tuberculosis antigens greatly influences disease
onset and progression. These crucial protective responses are
(1) acquired immunity to infection and (2) development of
tuberculin hypersensitivity.
DIAGNOSIS
A diagnosis of infection with M. tuberculosis relies on (1) development of a positive delayed hypersensitivity (tuberculin) skin
reaction to purified protein derivative (PPD), a mycobacterial
antigen isolated from bacterial cultures, and (2) demonstration
of acid-fast mycobacteria in clinical specimens. Information
obtained while collecting a patients medical history can provide evidence for suspicion of TB (Table 20-2).
RISK FACTORS
529
Infectious Diseases
TREATMENT
Prior to the advent of antimicrobial chemotherapy, approximately 50% of persons with active TB died within 2 years after
530
TUBERCULOSIS VACCINES
Principles of Medicine
Legionella
Scientists, clinicians, and the public officially became
acquainted with Legionella pneumophila as a result of the outbreak of legionnaires disease in a Philadelphia hotel housing the 1976 American Legion convention. As a result of the
first reports of sudden severe pneumonia among conventioneers, multiple epidemiologic groups were rapidly mobilized in an effort to determine both the cause(s) and contributory factors responsible for the 221 total cases and 34
illness-associated deaths.36
MICROBIAL CHARACTERISTICS
When the elusive etiologic bacterium was eventually isolated in 1977, using lung tissue from patients in the
531
Infectious Diseases
With regard to virulence factors, neither exotoxins nor destructive enzymes have been associated with the pneumonia caused
by L. pneumophila. The acute inflammatory infiltration and
febrile nature of clinical illness appear to be consistent with the
biologic manifestations of released endotoxin in tissues.
MODES OF TRANSMISSION
Legionella infections differ from other kinds of pneumoniainducing conditions in that the bacteria are not transmitted
from person to person but from contaminated environmental reservoirs. Evidence accumulated from outbreaks of the
disease and experimental investigations suggests that
Legionella species may be passed to susceptible hosts via multiple routes: aspiration, aerosolization, and instillation into
the lungs. Aspiration of contaminated water appears to be the
major means of human infection.44 In one study, passage of
microorganisms via this mechanism appeared to be exceptionally serious in patients after surgery for head and neck
cancer because of the patients frequency of aspiration of
fluids.45 Aerosolization of contaminated water occurs from
such sources as humidifiers, nebulizers, and cooling tower air
conditioners. Because the organisms are resistant to destruction in moist environments, it is believed that exposure to
legionellae is common. Reports in the literature in recent
years have implicated potable water harboring L. pneumophila as an important source of community-acquired
pneumonia. As a result, investigation of legionellosis cases
now includes examination of water supplies in patients
rooms, homes, and workplaces.4648
CLINICAL FEATURES
532
Principles of Medicine
Legionnaires Disease
Pontiac Fever
Epidemiology
Attack rate
< 5%
> 90%
Person-to-person spread
Clinical manifestations
Incubation period
No
No
210 d
12 d
Clinical features
Course
Self-limiting
Mortality
< 1%
Erythromycin was the historic antibiotic of choice for treatment of legionnaires disease. Timely appropriate chemotherapy can dramatically reduce the mortality rate of legionnaires
disease, with many patients showing signs of recovery within
3 to 5 days. With the advent of later-generation macrolides,
azithromycin has replaced erythromycin because of
azithromycins lower toxicity potential in a range of infected
patients.52 Quinolones also have been shown to be effective
antimicrobial agents in studies of patients with communityacquired pneumonia who are suspected of having L. pneumophila legionnaires disease.56,57 Antibiotic therapy is not
indicated for patients diagnosed with Pontiac fever because of
the self-limiting nature of the infection.
PROTOZOAL INFECTION:
CRYPTOSPORIDIUM
Although first isolated and identified in 1907,58 the protozoan
genus Cryptosporidium was not associated with human disease
until 1976.59 Only a few cases of cryptosporidiosis were
reported over the next few years, with those occurring in persons having severely compromised immune defenses. Since
the early 1980s, however, Cryptosporidium parvum has
emerged as a major etiology of persistent diarrhea in people of
developing countries, of severe life-threatening diarrhea in
persons with AIDS and other immunosuppressive conditions,
and in previously healthy individuals, as well as an increasingly
serious threat to the safety of the US water supply.
Microbial Characteristics
Among the most common of human pathogens, the diversity
of members within the protozoa has required their classification to be accomplished via disparate criteria, including phylogeny, epidemiology, and clinical manifestations. Protozoa
such as Plasmodium, Entamoeba, and Trypanosoma have long
been recognized as leading causes of human disease and mortality in many parts of the world. The dramatic increase in
numbers of individuals with less-than-adequate immune
defenses throughout the world, in part related to HIV infection with subsequent progression to AIDS, has also been
related to significant increases in other protozoan infections,
such as those caused by Cryptosporidium species.6065
533
Infectious Diseases
The type-species of this genus is C. parvum, which measures approximately 2.5 m in diameter, about the same size
and shape as yeast cells. It is capable of infecting and causing
disease in both humans and mammals. The infectious form of
C. parvum is a thick-walled oocyst that is excreted in feces
from infected hosts. Oocysts are resistant to standard municipal chlorination procedures, and this feature is important in
distinguishing cryptosporidia from many other unicellular
waterborne organisms. Because the oocysts can be found in
numerous natural water sources, they can readily cause large
cryptosporidiosis outbreaks when water treatment is less than
optimal and community supplies become contaminated.
Cryptosporidia are also unlike many other single-celled waterborne organisms in that they are highly resistant to the chlorine treatments used in municipal water facilities. In addition,
they are difficult to filter out because of their small size, and
thus they can escape the standard water treatment processes.
Clinical Syndrome
The complex C. parvum life cycle occurs within a single host.77
Symptoms of cryptosporidiosis may develop within 2 to 10
days after a person has swallowed environmentally contaminated water. The most common manifestations of C. parvum
infection are a profuse watery diarrhea, accompanied by fever,
severe abdominal cramping, and pain. Rapid dehydration of
patients is a major concern for physicians, as onset of diarrhea
can be quite sudden and can last for over 2 weeks.
Gastrointestinal symptoms abate in many patients with healthy
immune systems in about 2 weeks, although some may suffer
a relapse of the syndrome.78 The infection is typically more protracted and severe in immunocompromised hosts, however, as
extensive dehydration and weight loss may occur over a prolonged period of longer than 2 weeks. In some cases, multiple
intravenous infusions of fluids are required to replace body
fluids lost owing to diarrhea. Even after symptoms of cryptosporidiosis diminish or disappear, the patient can still transmit infectious parasites to others for months via contaminated
stools (fecal-oral transmission). Infected individuals with debilitated immune systems can remain infectious much longer.
534
VIRAL INFECTIONS
Hepatitis C Virus
Traditional health care concerns about viral hepatitis focused
primarily on hepatitis B virus (HBV) from the late 1940s to the
early 1980s. Yet, despite accumulated evidence for the documented occupational risks for HBV over a three-decade
period, significant voids from other potentially serious hepatitis challenges continue to require definition. Although the routine application of specific serologic tests was valuable in
screening and diagnosing infections caused by hepatitis A virus
(HAV) and HBV, a number of reports, written beginning in
1975, described a form of bloodborne post-transfusion hepatitis that could not be attributed to any known microorganism.79,80 Since diagnosis of this type of hepatitis was based on
abnormal liver function in the absence of positive blood markers for HAV, HBV, and other viruses known to cause hepatitis,
the term non-A, non-B hepatitis (NANBH) was introduced.
Most of the risk factors associated with NANBH transmission
were identified prior to recognition and characterization of its
viral etiology. These included blood transfusion, parenteral
drug use, health care worker exposure in clinical settings, sexual transmission from a person with a history of hepatitis, and
low socioeconomic status. Significant advances in recombinant
DNA technology were instrumental in the later isolation and
cloning of the responsible microorganism in 1989the
hepatitis C virus (HCV).81 A initial diagnostic serologic assay
was also developed for detection of antibodies to HCV (antiHCV) produced by infected persons against a recombinant
viral antigen c100-3.82 Later generations of more sensitive
immunoassays have been implemented since 1990. Currently,
at least six viral agents appear to account for the majority of
viral hepatitis cases (Table 20-10), with new information
emerging to expand this list.
VIROLOGY
Principles of Medicine
in various geographic areas, in an attempt to better define infection and disease patterns.86 Infection with HCV is also the most
common chronic bloodborne infection in the United States.
Current estimates range from 2.7 (1.3%) to 3.9 (1.8%) million
HCV-infected persons in the United States (Table 20-11).87,88
Approximately 2.7 million people are thought to have persistent chronic hepatitis C infection, and thus are classified as
potentially infectious viral carriers. Mortality in the United
States from all forms of hepatitis C infection is believed to
occur in 8,000 to 10,000 people each year. With the advent of
widespread use of anti-HCV assays and increased awareness of
documented risks and changing viral transmission patterns,
the incidence of new cases of acute hepatitis C has declined by
greater than 80% since 1989.
Statistics acquired during the 1970s and 1980s indicated
that parenteral NANBH was responsible for nearly 90% of
the reported US transfusion-associated hepatitis cases.
Accumulated data suggested that approximately 150,000 persons (5 to 10%) of 3,000,000 who received transfusions developed acute NANBH.89,90 With the advent of routine testing
using sensitive anti-HCV tests, however, the current risk for
acquiring transfusion-associated hepatitis C is 1/100,000 per
unit transfused.91 According to CDC national surveillance
data, parenteral drug use was the most common risk factor
reported by patients with NANBH between 1990 and 1992.
Injection-drug use remains the primary risk factor for new
cases of HCV infection. In addition, persons with hemophilia
who routinely received factor VIII or IX before 1987 and
chronic hemodialysis patients have also been considered at
risk. Occasionally, health care workers who have frequent contact with blood and personal contact with others who may be
infected have been documented to have an increased incidence
for hepatitis C compared with that of the general population.91,92 A summary of these and other epidemiologic estimates is presented in Table 20-12. In recent years, other serologic surveys have revealed a large previously undetected group
of persons at risk for HCV: military veterans, especially
Vietnam-era veterans. Testing at multiple Veterans
Administration (VA) hospitals found an 8 to 10% HCV prevalence rate, which is over four times that of the general population. Other reports indicate that more than half of the
patients receiving liver transplants in VA medical centers were
diagnosed with HCV infections.9395 Unfortunately, even with
improved epidemiologic tracking, published studies continue
to report that greater than 40% of the hepatitis C patients do
not have any identifiable risk factors.91 Evidence of sexual
transmission and of perinatal passage from HCV-infected
mothers to their offspring suggest possible, but not efficient,
modes of viral exposure. In summary, transmission data still
strongly implicate parenteral exposure as the primary mechanism for HCV transmission.
SEROLOGY
Picornaviridae; non-enveloped
single-stranded RNA
1540 d
Usually acute
Not present
No
None reported
0.10.2
Anti-HAV
Family characteristics
Incubation period
Onset
Prodome: arthritis/rash
Transmission
Carrier state
Possible manifestations
Homologous immunity
Anti-HBsAg
Hepatocellular carcinoma;
cirrhosis
Yes (510%)
Sometimes
Usually insidious
50180 d
Not defined
12
Hepatocellulalr carcinoma;
cirrhosis
Sometimes
Usually insidious
15 mo
Flaviviridae; enveloped
single-stranded RNA
Anti-HBsAg
220
Hepatocellular carcinoma;
cirrhosis
Yes
Unknown
Usually acute
2190 d
Satellite; non-enveloped
single-stranded RNA
Anti-HEV
12 in gen population;
20 in pregnant women
None reported
No
Fecal-oral; waterborne
(common in developing
countries)
Not present
Usually acute
29 wk
Caliciviridae; RNA
Adapted from Krugman S. Viral hepatitis: A, B, C, D, and Einfection. Pediatr Rev 1992;13:203; Molinari JA. Hepatitis C virus infection. Hepatitis C virus infection. Dent Clin North Am 1996;40:30925.
DNA = deoxyribonucleic acid; HBsAg = hepatitis B surface antigen; NA = not applicable; RNA = ribonucleic acid.
Feature
TABLE 20-10 Comparison of Major Microbiologic and Clinical Features of Hepatitis Viruses
Anti-HGV
NA
None reported
Yes
NA
NA
Flaviviridae; RNA
Infectious Diseases
535
536
Principles of Medicine
PATHOGENESIS
Presentation of viral hepatitis in patients ranges from asymptomatic illness to a fulminant chronic form in which severe
sequelae and high mortality rates are seen. Many chronic
hepatitis carriers are also at increased risk for hepatocellular
carcinoma. For those individuals who develop icteric manifestations of acute viral hepatitis, symptomatologies may vary
in intensity; yet they can be strikingly similar in their spectrum, regardless of the etiology. Disease presentations may
include jaundice, malaise, fever, anorexia, nausea, abdominal
pain, dark (stormy,foamy) urine, chalky gray stools, rash,
and arthritis.
The clinical features of HCV infection can be variable, in
patterns reminiscent of those observed for other hepatitis
viruses. Less than one-third of HCV-infected individuals
as a component of their routine donor screening. In a noteworthy positive outcome, the use of this radioimmunoassay
was found to yield positive anti-HCV results in 80 to 90% of
specimens from potential donors thought to be infectious for
HCV.97 Unfortunately, false-negative results are possible at
early stages of HCV infection since development of
detectable antibody could be delayed for months post viral
infection. This prolonged delay in seroconversion suggests
that some potentially infectious donors could pass undetected through screening, and their blood subsequently
TABLE 20-12 Estimated Average Prevalence of Hepatitis C Virus Infection in the United States*
Infection
Prevalence of
Persons with
Prevalence
Characteristic
Range %
Characteristic (%)
87
7490
< 0.01
79
7286
0.5
Injection-drug users
Current
No data
15
1018
10
064
50
616
1049
34
22
29
12
52
110
17
5
0.1
59
025
0.1
General population
1.8
218
1.52.3
NA
12
Pregnant women
1.5
Military personnel
0.3
0.20.4
0.5
0.16
NA = not applicable.
*By various characteristics and estimated prevalence of persons with these characteristics in the population.
537
Infectious Diseases
Applications
Comments
Sensitivity 97%
EIA alone has low positive-predictive value in lowprevalence populations
No clinical utility
rience frequent parenteral exposure to HCV via blood transfusion or intravenous drug use. High-risk sexual activity
may also be a factor.
At the present time, the demonstration and characterization of a protective host immune response against HCV have
not been accomplished. Presence of anti-HCV in a persons
blood does not distinguish between cases of acute or chronic
hepatitis C, nor can a positive test for this immunoglobulin
discriminate between a person who has recovered from infection with natural active immunity from one who has developed chronic hepatitis C.
OCCUPATIONAL RISKS TO HEALTH CARE PROFESSIONALS
538
Principles of Medicine
HBV
of Serum/Plasma
1,000,000100,000,000
6.030.0
HCV
101,000,000
2.76.0
HIV
101,000
0.30
Preliminary studies began appearing in the literature in the mid1980s that suggested that a prolonged course of therapy with
interferon- could have beneficial effects for persons with
chronic hepatitis C.110,111 These beneficial effects occurred
rapidly during therapy, with alanine aminotransferase (ALT) levels eventually falling to within the normal range. Follow-up testing after completion of the regimen unfortunately found the
ALT decline to be transient in most of the patients. Later investigations involving larger numbers of HCV-infected persons led
to FDA approval of a recombinant form of this antiviral agent for
treatment of chronic hepatitis C in 1991.112 Additional studies
have attempted to further refine therapeutic dosages and drug
regimen intervals.113
Combination of chemotherapeutic agents has shown
promising results in recent years. Currently, a daily regimen of
interferon -2b plus ribavirin for 6 to 12 months has demonstrated a significant improvement in patient biochemical and
virologic responses when compared with interferon monotherapy. Approximately 50% of treated patients have a sustained
beneficial response, compared with response rates of 15 to 25%
using interferon alone.114 Future therapies will probably
include additional multidrug approaches, such as other forms
of interferon and specific HCV enzyme inhibitors.115
An effective vaccine for hepatitis C is not yet commercially
available. Multiple factors have hindered research efforts
directed at prophylactic strategies. Two principal factors are the
failure to define a protective host immune response against
HCV infection, and the antigenic heterogeneity described for
different viral strains. Until scientists ascertain how host resistance develops during recovery from hepatitis C, and against
what antigen(s) the immunity is directed, vaccine studies will
continue to be limited. At present, routine use of universal
precautions during patient care and anti-HCV screening of
potential blood donors appears to be successful in reducing
health care provider, patient, and public exposures.
HIV Infection
Since the early 1980s, HIV has been recognized as one of the
most devastating infectious diseases of the twentieth century. By the end of the century, almost 60 million people
Infectious Diseases
worldwide had been infected with the virus, and the rate of
infection continued unabated. 116 The vast majority of
exposed and at-risk individuals had no access to effective
medications to combat the virus or its associated opportunistic infections. Even in the early stage of the twenty-first
century, there are few indications that there soon will be any
effective and affordable vaccines or anti-HIV medications
available for most people afflicted by this disease. This chapter explores many different aspects of HIV disease and
emphasizes oral health considerations, which impact on the
overall health of HIV-infected individuals.
EPIDEMIOLOGY
In June and July of 1981, the Centers for Disease Control published two reports on several clusters of young homosexual
men who developed opportunistic infections that were chiefly
detected in severely immunodeficient individuals.117,118 It was
not clear what caused this apparent immunodeficiency, and
the disease was initially referred to as gay-related immune
deficiency, or GRID. Several theories focusing on the lifestyle
of homosexual and bisexual men were put forth to explain the
cause of this illness. However, soon after, it became clear that
there were other groups in society who also developed this
rapidly evolving disease and that the cause was most probably
an infectious pathogen and not sexual preference.119125
It became evident that finding a causative agent, developing an accurate test to detect this pathogen, and elucidating the
modes of transmission were imperative to slow down the
quickly expanding epidemic. The etiologic agent of this disease,
now termed human immunodeficiency virus, was recognized
within 2 years of the first reported cases.126,127 Due to the severe
immunosuppression observed in affected individuals, this disease was eventually given the name acquired immunodeficiency syndrome. The CDC quickly put a surveillance system
in place. This surveillance system was based on standard case
definitions. Due to the changing nature of this disease, the original case definition from 1985 was expanded in 1987 and again
in 1993 to better incorporate specific illnesses in different populations as well as reflect changes in infected individuals
immune status128 (Table 20-16). AIDS, the stage of HIV disease
when individuals start to develop opportunistic infections or
have severe immunosuppression, is a reportable condition in all
50 states, the District of Columbia, and the US territories. At the
time of this writing, HIV infection is not a reportable condition
in all states. The number of total accumulated cases of AIDS
and the rate of AIDS in the United States are reported by the
CDC on a biannual basis129 (Table 20-17). Although the number of total accumulated cases of AIDS changes over time, the
ranking of states and metropolitan areas remains fairly stable.
More important than the actual number of cases and rates is the
trend of change. The directions of these trends reflect the course
of the HIV epidemic. Between June 1999 and June 2000, there
were an additional 42,563 persons who developed AIDS in the
United States. However, this represented a decrease of 7.6% of
new cases from 1998 to 1999. Also, the rate of AIDS per 100,000
population decreased by 8.2%. A decrease of 8.6% in new cases
539
540
Principles of Medicine
TABLE 20-16 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS among
Adolescents and Adults
CD4+ T-Lymphocyte Categories
The lowest accurate CD4+ T-lymphocyte count should be used for classification purposes, even though more recent and possibly different counts may be available.
Clinical Categories
Clinical category A
Conditions:
Asymptomatic human immunodeficiency virus (HIV) infection
Persistent generalized lymphadenopathy (PGL)
Acute HIV infection with accompanying illness or history of acute HIV infection
Conditions listed in category B and category C must not have occurred.
Clinical category B
Symptomatic conditions in HIV-infected adolescents or adults that are not included in clinical category C and meet at least one of the following criteria: (a) the conditions
are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; (b) the conditions are considered by physicians to have a clinical course or to
require management that is complicated by HIV infection.
Examples of, but not limited to, the following conditions:
Bacillary angiomatosis
Candidiasis, oropharyngeal (thrush)
Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to therapy
Cervical dysplasia (moderate or severe)/cervical carcinoma in situ
Constitutional symptoms, such as fever (38.5C) or diarrhea lasting > 1 mo
Herpes zoster (shingles) involving at least two distinct episodes or more than one dermatome
Idiopathic thrombocytopenia purpura
Listeriosis
Oral hairy leukoplakia
Pelvic inflammatory disease, particular if complicated by tubo-ovarian abscess
Peripheral neuropathy
Clinical category C
Conditions:
Candidiasis of bronchi, trachea, or lung
Candidiasis, esophageal
Cervical cancer, invasive
Coccidioidomycosis, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal (> 1 mo duration)
Cytomegalovirus disease (other than liver, spleen, or nodes)
Cytomegalovirus retinitis (with loss of vision)
Encephalopathy, HIV related
Herpes simplex: chronic ulcer(s) (> 1 mo duration); or bronchitis, pneumonitis, or esophagitis
Histoplasmosis, disseminated or extrapulmonary
Isosporiasis, chronic intestinal ( > 1 mo duration)
Kaposis sarcoma
Lymphoma, Burkitts (or equivalent term)
Lymphoma, immunoblastic (or equivalent term)
Lymphoma, primary, of brain
Mycobacterium avium-intracellulare complex or Mycobacterium kansasii, disseminated or extrapulmonary
Mycobacterium tuberculosis, any site (pulmonary or extrapulmonary)
Mycobacterium, other species or unidentified species, disseminated or extrapulmonary
Pneumocystis carinii pneumonia
Pneumonia, recurrent
Progressive multifocal leukoencephalopathy
Salmonella septicemia, recurrent
Toxoplasmosis
Wasting syndrome due to HIV infection
Clinical Categories
CD4+ T Cells/mm3 or
CD4+ Percentage
B: Symptomatic, no A or C Conditions
C: AIDS-Indicator Conditions
500 or 29%
200499 or 1428%
< 200 or < 14%
A1
A2
A3*
B1
B2
B3*
C1*
C2*
C3*
541
Infectious Diseases
New York
California
Florida
Texas
New Jersey
Illinois
Puerto Rico
Pennsylvania
Georgia
Maryland
Total Cases
139,248
117,521
78,043
52,667
41,245
24,425
24,061
23,678
22,197
20,833
Area of Residence
Rates
District of Columbia
New York
Virgin Islands, US
Florida
Maryland
Puerto Rico
Delaware
Massachusetts
New Jersey
South Carolina
189.4
39.4
37.6
33.4
27.2
26.4
26.3
24.4
23.6
20.9
New York, NY
Los Angeles, CA
San Francisco, CA
Miami, FL
Washington, DC
Chicago, IL
Houston, TX
Philadelphia, PA
Newark, NJ
Atlanta, GA
Metropolitan Area of Residence
New York, NY
Miami, FL
Fort Lauderdale, FL
San Francisco, CA
West Palm Beach, FL
Jersey City, NJ
Newark, NJ
Columbia, SC
Baltimore, MD
Washington, DC
Total Cases
117,792
42,394
27,567
23,521
22,321
21,173
18,735
18,348
16,739
15,524
Rates
68.1
58.3
56.9
52.6
50.5
43.2
40.3
39.7
35.9
35.8
PATHOGENESIS
542
Principles of Medicine
TABLE 20-18 Estimated Deaths and Rate of Change of Death of Persons with AIDS, in the United States
Measure
1993
1994
1995
1996
1997
1998
1999
45,381
49,869
50,610
37,787
21,923
17,930
16,273
+9.9
+1.5
25.3
42.0
18.2
9.2
Change (%)
543
Infectious Diseases
TABLE 20-19 Prediction of Immune Deterioration, HIV Disease Progression, and AIDS by HIV-1 RNA
HIV-1 RNA Copies/mL
< 500
5013,000
3,00110,000
10,00130,000
> 30,000
Decrease in Yearly
Individuals Dying
5.4
16.6
31.7
55.2
80.0
0.9
6.3
18.1
34.9
69.5
36.3
44.8
55.2
64.8
76.5
dence of opportunistic infections, AIDS incidence, and AIDSrelated deaths has slowed down. These latest trends are most
probably related to the development of resistance to antiretroviral drugs, transmission of HIV-resistant strains, and
the inability to maintain complete viral suppression for
extended periods of time in all individuals. Furthermore, several new opportunistic syndromes have been described in
patients given antiretroviral medications.154 It is possible that
this phenomenon, termed reversal syndromes, is due to a
rebounding immune system that initially does not have the
same antigenic divergence as developing nave CD4+ lymphocytes. This immune dysfunction may facilitate the development of latent opportunistic infections or unmask an undiagnosed opportunistic infection.
Apparently, not all individuals exposed to HIV become
infected. Furthermore, the rate of HIV disease progression in
individuals is highly variable. Some infected persons may
progress from infection to AIDS within months, whereas others have no signs of opportunistic infections or immune suppression even after 15 to 20 years. Approximately 10% of HIVinfected persons progress to AIDS within the 2 to 3 years after
infection, whereas 10 to 17% of infected individuals may not
develop AIDS even 20 years after infection.155 Obviously, these
subgroups of infected persons are of great interest, as they
may provide invaluable information regarding the variables
associated with infection, progression, and even immunity to
HIV, and subsequent treatment.
Numerous studies have focused on the ability and inability
of HIV to enter into target cells, and the capability of the
immune system to rid the body of the virus. During the earliest stages of HIV infection, the virus particularly seeks out and
19921995
3.4
4.7
0.2
19961998
21.5
39.9
16.7
544
Principles of Medicine
for viral replication. Included in these medications are amprenavir (APV), indinavir (IDV), nelfinavir (NFV), ritonavir
(RTV), and saquinavir (SQV). Due to the high level of toxicity and the rapid development of drug resistance, antiretroviral medications are given as double or triple therapy. This
combination therapy is referred to as highly active antiretroviral therapy, or HAART. Antiretroviral therapy is usually instituted when a patients CD4 cell count drops below a critical
value and/or when a patients viral load exceeds a critical level.
These predetermined values vary as better scientific information regarding the pathogenesis of HIV disease is elucidated
and depending on how patients react and respond to new and
better combinations of medications.
Prophylaxis against opportunistic infections is instituted
according to a patients immune status. Usually patients with
CD4 cell counts below 200 cells/mm3 are considered for prophylaxis to prevent Pneumocystis carinii pneumonia, and, at
even lower levels, prophylaxis is instituted against various fungal and mycobacterial infections. Knowledge about the type of
medications used to treat and prevent opportunistic infections helps the dental provider to attain additional insight into
a patients health status.
ORAL HEALTH CONSIDERATIONS
545
Infectious Diseases
Type of Drug
Co.
12
(+)-calanolide A*
NNRTI
Dysgeusia
NRTI
Peripheral neuropathy
NRTI
IBT
Not known
Aldesleukin or interleukin-2
(IL-2), Proleukin
IBT
Not known
PI
NRTI
BCH-10652* or dOTC*
NRTI
None
PI
Not known
Capravirine* (CPV)
Coactinon*, see emivirine*
NNRTI
Dysgeusia
Combivir combination of
zidovudine + lamivudine
NRTI
NRTI
Peripheral neuropathy
DAPD*
NRTI
Not known
13
NRTI
11
NRTI
NNRTI
DMP-450*
PI
Not known
13
DOTC* or BCH-10652*
NRTI
Not known
NNRTI
Continued
546
Principles of Medicine
Co.
NNRTI
Not known
13
NNRTI
Not known
13
PI
11
Drug Name*
NNRTI
Not known
GW-433908* or VX-175*
PI
IBT
Not known
CI
PI
Interleukin-2 (IL-2), or
aldesleukin, Proleukin
IBT
Not known
NRTI
Peripheral neuropathy
PI
PI
NNRTI
PI
Not known
PI
IBT
Not known
PI
11
Continued
547
Infectious Diseases
Type of Drug
Co.
PI
11
NRTI
Peripheral neuropathy
EI
Not known
14
NtRTI
Not known
Tipranavir* or PNU-140690*
PI
Not known
SVX-175* or GW-433908*
PI
NRTI
11
NRTI
CI = cellular inhibitor; EI = entry inhibitor (also fusion inhibitor); IBT = immune-based therapy; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside
reverse transcriptase inhibitor; NtRTI = nucleotide reverse transcriptase inhibitor; PI = protease inhibitor.
*Drug not approved by US Food and Drug Administration.
Pharmaceutical companies: 1-Abbott Laboratories; 2-Agouron Pharmaceuticals; 3-BioChem Pharma; 4-Boehringer Ingelheim ; 5-Bristol-Myers Squibb; 6-Chiron Corporation;
7-DuPont Pharmaceuticals; 8-Gilead Sciences; 9-Glaxo Wellcome; 10-Merck & Co.; 11-Roche Laboratories; 12-Sarawak Medichem; 13-Triangle Pharmaceuticals; 14- Trimeris.
There are no oral lesions that are unique to HIV-infected individuals. All lesions found among HIV-positive patients also
occur with other diseases associated with immune suppression. It is therefore not surprising to find a clear correlation
between the appearance of oral lesions and a decreased
immune system. Several lesions such as oral candidiasis, oral
hairy leukoplakia, necrotizing ulcerative periodontal disease,
and Kaposis sarcoma are strongly suggestive of impaired
immune response with CD4 cell counts below 200
cells/mm3.172174 Using oral lesions for markers of immune
548
Principles of Medicine
Date:
...............................................................................................................................
Chief complaint:
...............................................................................................................................
...............................................................................................................................
...............................................................................................................................
...............................................................................................................................
Purpose of disclosure:
...............................................................................................................................
...............................................................................................................................
Information to be disclosed:
...............................................................................................................................
...............................................................................................................................
Other
Witness signature: ................................................... Date...................................
Allergies and drug sensitivity:
Hepatitis (type and status):
FIGURE 20-7
Infectious Diseases
549
rioration.177 A tentative diagnosis of oral candidiasis is usually based on clinical appearance but should be confirmed by
laboratory tests. These tests include cytologic smears with
potassium hydroxide, biopsy for periodic acidSchiff and
Gram staining for tissue infiltration by spores and hyphae, or
culture.178 In general, oral candidiasis has four different clinical presentations, as follows:
1. Pseudomembranous candidiasis, or thrush. This condition is a common type of oral candidiasis. It manifests
as white or yellowish single or confluent plaques that
can easily be rubbed off from the oral mucosa (Figure
20-9). It is found on all oral surfaces and may leave an
erythematous or even bleeding underlying mucosa.
Most patients are not aware of the presence of this form
of candidiasis as pseudomembranous candidiasis is
predominantly asymptomatic. The condition is noticed
most commonly when CD4 cells counts drop below
400 cells/mm3.
2. Erythematous or atrophic candidiasis. This condition appears on any mucosal surface as a reddish
macular lesion, atrophic patches, or depapillation on
the dorsum of tongue (Figure 20-10). Erythematous
candidiasis may be present alone or in combination
with the pseudomembranous type. Patients may
complain of an occasional burning sensation in the
mouth. Long-standing lesions may even present as
mucosal ulcerations.
3. Hyperplastic or chronic candidiasis. This form of candidiasis is relatively uncommon and is found mainly in
persons who are severely immunocompromised.
Hyperplastic candidiasis, manifesting as white or discolored plaques that may be solitary or confluent and
cannot be wiped off the mucosa, may be confused with
oral hairy leukoplakia when located on the tongue only
(Figure 20-11). Complaints of a burning sensation, dysphagia, and a feeling of having a large piece of cotton
in the mouth are not unusual. This type of oral candidiasis is often present with esophageal candidiasis.
4. Angular cheilitis. This condition, which is predominantly a mixed infection involving C. albicans and
Staphyloccocus aureus, manifests itself as red fissures
originating from the labial commissures of the mouth
(Figure 20-12). Angular cheilitis may be present with
intraoral candidiasis. Concurrent oral dryness also is
not uncommon. Angular cheilitis has been associated
with vitamin B deficiency and decreased vertical
dimension of occlusion from either periodontal disease or ill-fitting dentures. Therefore, it is important to
address concurrent conditions as antifungal treatment
is instituted.
550
Principles of Medicine
FIGURE 20-12 A, Angular cheilitis is commonly caused by Candida albicans. This lesion usually manifests with an ulcer at the corner of the mouth,
with erythematous fissures radiating from the ulcer. A pseudomembrane sometimes covers the ulcers. B, Treatment with topical antifungal medications and
antibiotics, for bacterial superinfections, is usually efficacious.
Infectious Diseases
551
infectious mononucleosis, Burkitts lymphoma, nasopharyngeal carcinoma, and oral hairy leukoplakia. Oral hairy leukoplakia was initially described in individuals with HIV disease,
but it has since been found in many other patient populations. This lesion may be present in all phases of HIV disease,
but it is most commonly found in individuals with CD4 cell
counts below 200 cells/mm3. It manifests as an asymptomatic
white lesion, most frequently with vertical hyperkeratotic striae
that are usually seen on the lateral borders of the tongue187
(Figure 20-13). The lesion may vary from linear striae to white
patches that cannot be wiped off, and they often have white
hyperkeratotic hairlike projections. Because of its clinical characteristics, differential diagnosis should include hyperplastic
candidiasis. Although it is not thought that Candida albicans
contributes to the clinical appearance of oral hairy leukoplakia,
C. albicans may be present in more than 50% of oral hairy
leukoplakia lesions. When definitive diagnosis of oral hairy
leukoplakia needs to be established, it is necessary to verify the
presence of EBV in the superficial layers of the involved epithelium. Owing to the significant association between this lesion
and HIV, a biopsy is necessary to rule out oral hairy leukoplakia in patients yet to be tested for HIV. In HIV-positive
individuals, an empiric diagnosis can be inferred when a clinical lesion resembling oral hairy leukoplakia does not respond
to antifungal medications.
It is important to assure the patient that the presence of
oral hairy leukoplakia has not been associated with person-toperson transmission of EBV.
Treatment of this lesion usually is not indicated unless the
patient complains of esthetic disfiguration or masticatory
functional impairment. Antiviral therapy (acyclovir 800 mg
orally five times a day) is effective to achieve resolution of the
552
lesion within 2 weeks. Prophylactic therapy with 800 mg acyclovir per day may be necessary to prevent recurrence.
Varicella-Zoster Virus. There have been reports of
increased incidence of human varicella-zoster virus (HZV)
infections among HIV-infected persons, relative to increased
age and degree of immunosuppression. Complications associated with HZV in immunocompromised patients are common and can be severe, especially for those individuals with
CD4 counts fewer than 200 cells/mm3.188 Clinically, oral
HZV infection presents as vesicles that quickly rupture,
resulting in ulcerations. The ulcers are multiple, shallow,
and small, with an erythematous base, and are characteristically distributed unilaterally along a division of the fifth
cranial nerve. Patients frequently complain of pain, neuropraxia, and tenderness. Although clinical presentation is distinct for HZV infection, a definitive diagnosis should be
confirmed by laboratory tests such as histologic staining for
multinucleated giant cells with intranuclear inclusions,
direct immunofluorescence, and cytology smears taken from
the lesion.
Treatment usually is focused on supportive care and is centered on the prevention of postherpetic neuralgia and dissemination. High doses of oral acyclovir (800 mg orally five
times a day), famciclovir (500 mg orally three times a day), or
valacyclovir (500 mg orally three times a day) have been efficacious in treating HZV infection. Caution is needed when
using valacyclovir in severely immunosuppressed patients as
this medication has been associated with hemolysis in this
particular patient population. For greatly immunosuppressed
patients, intravenous acyclovir therapy may be more appropriate. Foscarnet also may be useful for acyclovir-resistant herpes zoster.189 It has been reported that there are high incidences of herpes zoster in patients shortly after they start
treatment with protease inhibitors, which might suggest a need
for prophylaxis for those at increased risk for developing herpes zoster infection.190
Principles of Medicine
FIGURE 20-14 A, Initial lesions of Kaposis sarcoma are usually found on the hard and soft palates. These lesions are commonly bluish-red macules.
B, Long-standing palatal lesions may become nodular and even ulcerative.
553
Infectious Diseases
FIGURE 20-15 Human papillomavirus has become more common in individuals whose immune system is undergoing changes, such as reconstitution
after severe CD4 cell depletion. Florid lesions may affect the lips (A) and intraoral mucosa (B).
squamous cell papillomas may present as exophytic pedunculated papules with a cauliflower-like appearance. Verruca
vulgaris (the common wart) is a firm, sessile, exophytic, and
whitish lesion. This form of HPV presentation also has a
hyperkeratinized superficial epithelium with a slight invagination of the center of the lesion. Focal epithelial hyperplasia (Hecks disease) may present as a single or multiple,
smooth or pebble-like, hyperplastic leukoplakic lesion. Focal
epithelial hyperplasia is commonly found on keratinized tissues such as the alveolar mucosa and the lips. Condyloma
acuminatum presents as small white-to-pink nodules with
a pebbled surface and is most commonly found on the soft
and hard palates and the tongue.195 The presence of HPVassociated lesions is not pathognomonic for HIV infection
or progression. However, an increase in the prevalence of
oral HPV infections among HIV-infected persons has been
reported since the introduction of protease inhibitors.
Although most of oral HPV manifestations are asymptomatic, unless lesions are induced by trauma, they can interfere
with mastication and may raise cosmetic concerns. Treatments
for HPV include surgical removal, laser ablation, cryotherapy,
and topical application of keratinolytic agents. For smaller
lesions, topical application of 25% podophyllum resin may be
used to reduce the size. A more novel approach has been the use
of intralesional injection of antiviral agents. Interferon- in
intralesional injections (1,000,000 IU/cm2 once weekly) and
subcutaneous injections (3,000,000 IU/cm2 twice weekly) have
been shown to be effective in long-term resolution of lesions.196
Bacterial Infection. Periodontal Disease. The most common oral manifestations of bacterial origin are associated
with periodontal conditions. These conditions are usually categorized by their clinical appearance and include linear gingival erythema (LGE), necrotizing ulcerative gingivitis
(NUG), and necrotizing ulcerative periodontitis (NUP). It
has also been noted that HIV-seropositive patients with previous periodontal disease may show faster rates of conventional periodontal deterioration as compared with those of
HIV-seronegative persons. Lamster and colleagues have suggested that the progression of periodontal disease in HIVinfected persons is dependent on the immunologic competency of the host and local host response to typical and
atypical microorganisms related to periodontal disease.197
Thus, the level of immune suppression, as demonstrated by
decreasing number of T-cell lymphocytes, in combination
with the degree of plaque accumulation, may explain these
conditions in HIV-infected patients.173
Linear gingival erythema is an atypical gingivitis that is
depicted as a 2 to 3 mm distinct band of fiery redness at the
marginal gingiva around the teeth (Figure 20-16). Such erythema is not proportional to the plaque accumulation and
seems to only affect the soft tissue, without any ulcerations,
increased pocket depths, or any attachment loss. Patients with
this condition are usually asymptomatic. The true prevalence
of LGE is difficult to determine due to variable diagnostic criteria that have been put forth.
Differential diagnosis should include a localized erythema
due to dry mucosa associated with mouth breathing, lichen
planus, mucous membrane pemphigoid, or an allergic reaction.
The most recent theory regarding the pathogenesis of this lesion
implicates subgingival candida infection as a possible cause.197
554
Treatments include improved oral home care and conventional dental scaling and root planing, along with the use of
chlorhexidine gluconate (0.12%) mouth rinses (15 mL
swished and expectorated twice a day) for up to 3 months.
Additionally, concomitant use of topical antifungal medications may be beneficial.
Manifestations of NUG and NUP are triggered by changes
in the immune status, most probably aggravated by intraoral
bacteria. The two entities may present as a continuum of the
same disease but also may appear as separate entities. NUG is
limited to the gingiva (Figure 20-17), whereas NUP is characterized by localized to generalized aggressive alveolar bone and
attachment destruction (Figure 20-18). Occurrence of NUG
has been associated with stress, anxiety, malnutrition, and smoking. Patients with NUG complain of spontaneous gingival bleeding and mild to moderate gingival pain. NUP is associated with
complaints of deep-seated bone pain, spontaneous gingival
bleeding, halitosis, and tooth mobility. Clinically, these conditions are presented with initial lesions of limited craterlike
necrosis of gingival papillae. When untreated, NUP may
progress at a rate of 1 to 2 mm of soft- and hard-tissue destruction per week. NUP is mostly seen with severe immune suppression, with CD4 counts below 100 cells/mm3.173
A definitive diagnosis is based on clinical evaluation and
radiologic evaluation with panoramic radiographs or specific
periapical dental radiographs. Specific laboratory tests may be
needed to rule out conditions and lesions such as bullous lesions
of benign mucous membrane pemphigoid, erythema multiforme, acute forms of leukemia, and major aphthous ulceration.
Treatment for both NUG and NUP consists of dbridement of necrotic soft and hard tissue, antibiotic therapy with
metronidazole or tetracycline (500 mg four times a day) for
a week, and a follow-up with scaling and dbridement.173
Due to the high risk for fungal infections in these patients, an
antifungal regimen may be prescribed together with the
antibiotics. Chlorohexidine gluconate (0.12%) mouth rinses
are recommended as maintenance therapy. Metronidazole
should be used with caution in patients who are taking
lopinavir and retonavir.
Principles of Medicine
Tuberculosis. Intraoral lesions associated with TB may present as single nonhealing caseating granulomatous ulcerations that are accompanied by deep-seated pain. The lesions
have been noted on the tongue, the palate, the buccal mucosa,
and the angles of the mouth.198 Diagnosis by clinical presentation alone is difficult and needs to be complemented
with demonstration of acid-fast TB bacilli within the
lesion.199 Treatment is locally palliative as an adjunct to systemic TB therapy.
Syphilis. Clinical presentation of syphilis includes chancres,
snail-track ulcers, and gumma formation.200 Chancres are
mostly asymptomatic indurated ulcers with a brown crusted
appearance that are usually seen on the lips, oral mucosa,
tongue, palate, and posterior pharyngeal wall. Secondary
syphilis is characterized by highly infectious mucosal ulcers
with an appearance of white lesions surrounded by an erythematous base. Frank ulceration is most common in tertiary
syphilis as a result of gummatous destruction. It is usually
seen on the palate and tongue.
Differential diagnosis should include herpetic cold sores,
deep-seated fungal infections, mycobacteria-associated ulcer,
malignant ulcers, and trauma. A definitive diagnosis is made
by dark-field microscopy that demonstrates the etiologic
agent, Treponema pallidum. Treatment is based on appropriate systemic antibiotic therapy.
Nonspecific Ulcerations. Necrotizing Stomatitis. Necrotizing
stomatitis is a localized acute painful ulcerative lesion on
mucosal surfaces overlying bone (Figure 20-19). This condition
eventually leads to necrosis of tissue and subsequent bone exposure. No specific microbial agent or mechanism has been linked
to its etiology. This condition is seen in patients with CD4 cells
fewer than 100 cells/mm3.168 Differential diagnosis includes
aphthous ulcer and NUP. Treatment consists of careful dbridement, local or systemic steroid therapy, antibiotics, and institution of a soft-tissue stent to protect the affected area from further trauma and for delivery of topical medications.201
Aphthous Ulcers. Recurrent aphthous ulcerations (RAUs)
are idiopathic oral ulcerations. There are three disease entities of RAUs: minor, major, and herpetiform. Diagnosis of
RAUs is a diagnosis of exclusion; the clinical impression
should be confirmed with histologic examination and by
response to treatment.179
Minor (recurrent) aphthous ulcerations are smaller than
10 mm in diameter, well-circumscribed, round, sometimes
covered by a yellow-gray pseudomembrane, and surrounded
by an erythematous halo. The erythematous halo may be
absent in severely immunocompromised patients due to their
lack of an intact inflammatory response. Minor aphthous
ulcerations are usually confined to the nonkeratinized oral
mucosa and tend to recur, often at the same site. Their duration is about 1 to 2 weeks, and healing occurs without scarring.
Minor aphthous ulcerations are prevalent in both nonHIVinfected populations and HIV-infected populations.
555
Infectious Diseases
556
Principles of Medicine
A
FIGURE 20-20
B
A, Major aphthous ulcer in the retromolar region in an HIV-infected patient. B, The same major aphthous ulcer, after treatment.
Infectious Diseases
REFERENCES
1. Burnet M. Natural history of infectious disease. Cambridge:
Cambridge University Press; 1962.
2. Institute of Medicine. Emerging infections: microbial threats
to health in the United States. Washington: National Academy
Press; 1992.
3. Centers for Disease Control and Prevention. Achievements in
public health, 19901999: control of infectious diseases.
MMWR Morb Mortal Wkly Rep 1999;48:6219.
4. Centers for Disease Control and Prevention. Tuberculosis and
acquired immunodeficiency syndromeFlorida. MMWR
Morb Mortal Wkly Rep 1986; 35:587.
5. Centers for Disease Control and Prevention. Tuberculosis morbidity in the United States: final data, 1990. MMWR Morb
Mortal Wkly Rep 1991;40(SS-3):23.
6. Bernardo J. Tuberculosis: a disease of the 1990s. Hosp Pract
1991;26:195.
7. Centers for Disease Control and Prevention. Tuberculosis morbidityUnited States, 1997. MMWR Morb Mortal Wkly Rep
1998;47:253.
8. American Thoracic Society. Control of tuberculosis in the
United States. Am Rev Respir Dis 1992;146:1623.
9. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 19902000. Bull World Health
Org 1994;72:213.
10. World Health Organization. Report on the tuberculosis epidemic. Geneva, Switzerland: WHO; 1997.
11. Centers for Disease Control and Prevention. Summary of notifiable diseases1998. MMWR Morb Mortal Wkly Rep
1999;47:70.
12. Centers for Disease Control and Prevention. World TB day
March 24, 2001. MMWR Morb Mortal Wkly Rep 2001;50:201.
13. Centers for Disease Control and Prevention. Core curriculum
on tuberculosis. 3rd ed. Atlanta: US Department of Health
and Human Services; 1994.
14. Bates JH, Stead WW. The history of tuberculosis as a global
epidemic. Med Clin North Am 1993;77:1205.
15. Orme IM, Anderson P, Boom WH. T cell response to
Mycobacterium tuberculosis. J Infect Dis 1993;167:1481.
16. Ellner JJ. The immune response in human tuberculosis: implications for tuberculosis control. J Infect Dis 1997;176:1351.
17. Mani NJ. Tuberculosis initially diagnosed by asymptomatic
oral lesions. J Oral Med 1985;40:39.
18. Molinari JA, Chandrasekar PH. Mycobacteria. In: Willett NP,
White RR, Rosen S, editors. Essential dental microbiology.
Norwalk: Appleton and Lange; 1991. p. 181.
19. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the
risk of tuberculosis among intravenous drug users with human
immunodeficiency virus infection. N Engl J Med 1989;320:545.
20. Reider HL, Jereb JA, Frieden TR, et al. Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989;11:79.
21. Theuer CP, Hopewell PC, Elias D, et al. Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis
1990;162:8.
22. Small PM, Schecter GF, Goodman PC, et al. Treatment of
tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991;324:289.
23. Barnes PF, Bloch AB, Davidson PT, et al. Tuberculosis in
patients with human immunodeficiency virus infection. N
Engl J Med 1991;324:164450.
557
24. Styblo K. Recent advances in epidemiological research in
tuberculosis. Adv Tuberc Res 1980;20:1.
25. Van Scoy RE, Wilkowske CJ. Antituberculous agents. Mayo
Clin Proc 1992;67:179.
26. Centers for Disease Control and Prevention. Initial therapy
for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of
Tuberculosis. J Am Med Assoc 1993;270:696.
27. Cohen ML. Epidemiology of drug resistance: implications for
a post-antimicrobial era. Science 1992;257:1050.
28. Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence
of drug-resistant tuberculosis in New York City. N Engl J Med
1993;328:521.
29. Shearer BG. MDR-TB: another challenge from the microbial
world. J Am Dent Assoc 1994;125:43.
30. Raviglione MC, Dye C, Schmidt S, et al. Assessment of worldwide tuberculosis control. WHO global surveillance and monitoring project. Lancet 1997;350:624.
31. Luelmo F. BCG vaccination. Am Rev Respir Dis 1982;125:70.
32. Jacobs JR Jr. Advances in mycobacterial genetics: new promises
for old diseases. Immunobiol 1992;184:147.
33. Cleveland JL, Gooch DF, Bolyard EA, et al. TB infection control recommendations from the CDC, 1994: considerations
for dentistry. J Am Dent Assoc 1995;126:593.
34. US Department of Health and Human Services, Centers for
Disease Control and Prevention. Guidelines for preventing the
transmission of Mycobacterium tuberculosis in healthcare facilities. MMWR Morb Mortal Wkly Rep 1994;43(RR-13):1.
35. Field MJ, editor. Tuberculosis in the workplace. Washington
(DC): National Academy Press; 2001.
36. Fraser DW, Tsai TR, Orenstein W, et al. Legionnaires disease:
description of an epidemic of pneumonia. N Engl J Med
1977;297:1189.
37. Centers for Disease Control and Prevention. Follow-up on respiratory illnessPhiladelphia. MMWR Morb Mortal Wkly
Rep 1977; 26:9.
38. McDade JE, Shepard CC, Fraser DW, et al. Legionnaires disease: isolation of a bacterium and demonstration of its role in
other respiratory disease. N Engl J Med 1977;297:1197.
39. Brenner DJ, Steigerwalt AG, McDade JE. Classification of the
legionnaires disease bacterium: Legionella pneumophila, genus
novum, species nova, of the family Legionellaceae, family nova.
Ann Intern Med 1978;90:656.
40. McDade JE, Brenner DJ, Bozeman FM. Legionnaires disease
bacterium isolated in 1947. Ann Intern Med 1979;90:659.
41. Rowbotham TJ. Current views on the relationship between
amoebae, legionellae, and man. Isr J Med Sci 1986;22:1218.
42. Rowbotham TJ. Isolation of Legionella pneumophila from clinical specimens via amoebae, and the interaction of those and
other isolates with amoebae. J Clin Pathol 1983;36:978.
43. Stout JE, Yu VL, Best M. Ecology of Legionella pneumophila
within water distribution systems. Appl Environ Microbiol
1985;49:221.
44. Muder R, Yu VL, Woo A. Mode of transmission of Legionella
pneumophila: a critical review. Arch Intern Med 1986;146:1607.
45. Johnson JT, Yu VL, Best M, et al. Nosocomial legionellosis
uncovered in surgical patients with head and neck cancer:
implications for epidemiologic reservoir and mode of transmission. Lancet 1985;2:298.
46. Stout JE, Yu VL, Muraca ME, et al. Potable water as a cause of
sporadic cases of community-acquired pneumonia. N Engl J
Med 1992;326:151.
558
47. Shands K, Ho J, Meyer R, et al. Potable water as a source of
legionnaires disease. J Am Med Assoc 1985;253:1412.
48. Stout JE, Yu VL, Muraca P. Legionnaires disease acquired
within the homes of two patients: link to the home water supply. J Am Med Assoc 1987;257:1215.
49. Kaufman AF, McDade J, Patton C, et al. Pontiac fever: isolation
of the etiologic agent (Legionella pneumophila) and demonstration of its mode of transmission. Am J Epidemiol
1981;114:337.
50. Fotos PG, Westfall HN, Snyder IS, et al. Prevalence of
Legionellaspecific IgG and IgM antibody in a dental clinic
population. J Dent Res 1985;64:1382.
51. Reinthaler FF, Mascher F, Stunzer D. Serological examinations
for antibodies against Legionella species in dental personnel. J
Dent Res 1988;67:942.
52. Yu VL. Legionella pneumophila (legionnaires disease). In:
Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Churchill Livingstone; 2000.
p. 2424.
53. Centers for Disease Control and Prevention. Sustained transmission of nosocomial legionnairesdiseaseArizona and
Ohio. MMWR Morb Mortal Wkly Rep 1997;46:416.
54. Lowry PW, Tompkins LS. Nosocomial legionnellosis: a review
of pulmonary and extrapulmonary syndromes. Am J Infect
Control 1993;21:21.
55. Kirby BD, Snyder KM, Meyer RD, et al. Legionnaires disease:
report of sixty-five nosocomially-acquired cases and review of
the literature. Medicine 1980;59:188.
56. Seu P, Winston DJ, Olthoft KM, et al. Legionnaires disease in
liver transplant recipients. Infect Dis Clin Pract 1993;2:109.
57. Singh N, Muder RR, Yu VL, et al. Legionella infection in liver
transplant recipients: implications for management.
Transplantation 1993;56:1549.
58. Tyzzer EE. A sporozoan found in the peptic glands of the common mouse. Proc Soc Exp Biol Med 1907;5:12.
59. Nime FA, Burek JD, Page DL, et al. Acute gastroenterocolitis in
a human being infected with the protozoan Cryptosporidium.
Gastroenterol 1976;70:592.
60. Current WL. Human cryptosporidiosis. N Engl J Med
1983;309:1325.
61. Peterson C. Cryptosporidiosis in patients infected with the
human immunodeficiency virus. Clin Infect Dis 1992;15:903.
62. Laughon BE, Druckman DA, Vernon A, et al. Prevalence of
enteric pathogens in homosexual men with and without
acquired immunodeficiency syndrome. Gastroenterol
1988;94:984.
63. Smith PD, Lane HC, Gill VJ, et al. Intestinal infections in
patients with the acquired immunodeficiency syndrome. Ann
Intern Med 1988;108:328.
64. Pederson C, Danner S, Lazzarin A, et al. Epidemiology of cryptosporidiosis among European AIDS patients. Genitourin Med
1996;72:128.
65. Vakil NB, Schwartz SM, Buggy BP, et al. Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. N Engl J Med
1996;334:19.
66. Haas CN, Rose JB. Reconciliation of microbial risk models
and outbreak epidemiology: the case of the Milwaukee outbreak. Proc Am Water Works Assoc 1994;517.
67. Fricker C, Crabb J. Waterborne cryptosporidiosis: detection
methods and treatment options. Adv Parasitol 1998;40:242.
Principles of Medicine
68. MacKenzie WR, Hoxie NJ, Proctor ME, et al. A massive outbreak in Milwaukee of Cryptosporidium infection transmitted
through the public water supply. N Engl J Med 1994;331:161.
69. Hayes EB, Matte TD, OBrien TR, et al. Large community outbreak of cryptosporidiosis due to contamination of a filter
public water supply. N Engl J Med 1989;320:1372.
70. McAnulty JM, Fleming DW, Gonzalez AH. A community-wide
outbreak of cryptosporidiosis associated with swimming at a
wave pool. J Am Med Assoc 1994;272:1597.
71. Goldstein ST, Juranek DD, Ravenholt O, et al. Cryptosporidiosis:
an outbreak associated with drinking water despite state-of-theart water treatment. Ann Intern Med 1996;124:459.
72. Newman RD, Zu S-X, Wuhib T, et al. Household epidemiology
of Cryptosporidium parvum infection. Ann Intern Med
1994;120:500.
73. Cordell RL, Addiss DG. Cryptosporidiosis in child care settings: a review of the literature and recommendations for prevention and control. Pediatr Infect Dis 1994;13:311.
74. Koch RL, Phillips DJ, Aber RC, et al. Cryptosporidiosis in hospital personnel. Ann Intern Med 1985;102:593.
75. Miron D, Kenes J, Dagan R. Calves as a source of an outbreak
of cryptosporidiosis among young children in an agricultural
closed community. Pediatr Infect Dis 1991;10:438.
76. Millard PS, Gensheimer KF, Addiss DG, et al. An outbreak of
cryptosporidiosis from fresh-pressed apple cider. J Am Med
Assoc 1994;272:1592.
77. Ungar BLP. Cryptosporidium. In: Mandell GL, Bennett JE,
Dolan R, editors. Principles and practice of infectious diseases.
5th ed. New York: Churchill Livingstone; 2000. p. 2903.
78. Dupont H, Chappell C, Sterling C, et al. The infectivity of
Cryptosporidium parvum in healthy volunteers. N Engl J Med
1995;332:885.
79. Alter HJ, Holland PV, Purcell RH. The emerging pattern of
post-transfusion hepatitis. Am J Med Sci 1975;270:329.
80. Alter HJ, Purcell RH, Holland PV, et al. Clinical and serological analysis of transfusion-associated hepatitis. Lancet
1975;2:838.
81. Choo Q-L, Kuo G, Weiner, et al. Isolation of a cDNA clone
derived from a blood-borne non-A, non-B viral hepatitis
genome. Science 1989;244:359.
82. Kuo G, Choo Q-L, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B
hepatitis. Science 1989;244:362.
83. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of
hepatitis C virus: quasispecies and genotypes. Semin Liver Dis
1995;15:41.
84. Cha T-A, Beall E, Irvine B, et al. At least five related, but distinct,
hepatitis C viral genotypes exist. Proc Natl Acad Sci U S A
1992;89:7144.
85. Chan S-W, McOmish F, Holmes EC, et al. Analysis of a new
hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 1992;73:1131.
86. Rall CJN, Dienstag JL. Epidemiology of hepatitis C virus infection. Semin Gastrointest Dis 1995;6:3.
87. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence
of hepatitis C virus infection in the United States, 1988 through
1994. N Engl J Med 1999;341:556.
88. Seeff LB. Natural history of viral hepatitis, type C. Semin
Gastrointest Dis 1995;6:20.
89. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 1983;85:439.
559
Infectious Diseases
90. Koretz RL, Abbey H, Coleman E, et al. Non-A, non-B posttransfusion hepatitis: looking back on the second decade. Ann
Intern Med 1993;119:110.
91. Centers for Disease Control and Prevention. Recommendations
for prevention and control of hepatitis C virus (HCV) infection
and HCV-related chronic diseases. MMWR Morb Mortal Wkly
Rep 1998;47(RR-19):1.
92. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis
C virus from mothers to infants. N Engl J Med 1994;330:744.
93. Liang JT, Rhermann J, Seeff LB, et al. NIH conference: pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296.
94. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future
burden of chronic liver disease in the United States.
Hepatology 2000;31:777.
95. American Health Consultants. Fasten your seat belts: hospitals
face a bumpy ride as hepatitis C cases peak. Hosp Infect Cont
2000;27:129.
96. Food and Drug Administration. New blood screening tests for
hepatitis C. FDA Drug Bull 1990; October: 9.
97. Roth WK, Lee JH, Ruster B, et al. Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. J Clin
Microbiol 1996;34:261.
98. Alter MJ, Hadler SC, Judson FN, et al. The natural history of
community-acquired hepatitis C in the United States. N Engl
J Med 1992;327:1899.
99. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C infection
in post-transfusion hepatitis: an analysis with first- and second-generation assays. N Engl J Med 1991;325:1325.
100. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up
of non-A, non-B (type C) post-transfusion hepatitis. J
Hematol 1992;16:273.
101. Alter HJ, Seeff LB: Recovery, persistence and sequelae in
hepatitis C infection: a perspective on long-term outcome.
Semin Liver Dis 2000;20:17.
102. Kiyosawa K, Sodeyama T, Tanaka E, et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med
1991;115:367.
103. Lanphear BP, Linneman CC Jr, Cannon CG, et al. Hepatitis C
virus infection in healthcare workers: risk of exposure and
infection. Infect Control Hosp Epidemiol 1994;15:745.
104. Schlipkoter U, Roggendorf M, Cholmakow K, et al.
Transmission of hepatitis C (HCV) from a hemodialysis patient
to medical staff member. Scand J Infect Dis 1990;22:757.
105. Vaglia A, Nicolin R, Puro V, et al. Needlestick hepatitis C seroconversion in a surgeon. Lancet 1990;336:1315.
106. Ippolito G, Puro V, Petrosillo N, et al. Simultaneous infection
with HIV and hepatitis C virus following occupational conjunctival blood exposure. J Am Med Assoc 1998;280:28.
107. Klein RS, Freeman K, Taylor PE, et al. Occupational risk for
hepatitis C infection among New York City dentists. Lancet
1991;338:1539.
108. Cleveland JL, Gooch BF, Shearer BG, et al. Risk and prevention
of hepatitis C infection: implications for dentistry. J Am Dent
Assoc 1999;130:641.
109. Lanphear BP. Trends and patterns in the transmission of
bloodborne pathogens to health care workers. Epidemiol Rev
1994;16:437.
110. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of
chronic non-A, non-B hepatitis with recombinant human
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
560
130. Bozzette S, Berry SH, Duan N, et al. The care of HIV-infected
adults in the United States. N Engl J Med 1998;339:1897.
131. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the
chimpanzee Pan troglodytes. Nature 1999;396:437.
132. Hahn BH, Shaw GM, De Cook KM, et al. AIDS as a zoonosis; scientific and public health implications. Science 2000;287:6076.
133. Ciesielski CA, Marianos DW, Schochetman G, et al. The 1990
Florida dental investigation. The press and the science. Ann
Intern Med 1994;121:886.
134. Piatak M, Saag MS, Lang LC, et al. High levels of HIV-1 in
plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749.
135. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and
viral generation time. Science 1996;271:1582.
136. Coffin JM. HIV population dynamics in vivo: implications for
genetic variation, pathogenesis, and therapy. Science
1995;267:483.
137. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes
in human immunodeficiency virus type 1 RNA load and
appearance of drug-resistant virus populations in persons
treated with lamivudine (3TC). J Infect Dis 1995;171:1411.
138. Stein DS, Korvick JA, Vermund SH. CD4+ lymphocyte cell
enumeration for prediction of clinical course of human
immunodeficiency virus disease: a review. J Infect Dis
1992;165:352.
139. Mellors JW, Munoz A, Giorgi J, et al. Plasma load and CD4+
lymphocytes as prognostic markers of HIV-1 infection. Ann
Intern Med 1997;126:946.
140. Mulder J, McKinney N, Christopherson C, et al. A rapid and
simple PCR assay for quantification of HIV-1 RNA in plasma:
application to acute retroviral infection. J Clin Microbiol
1994;32:292.
141. Welles SL, Jackson JB, Yen-Lieberman B, et al. Prognostic value
of plasma human immunodeficiency virus type 1 (HIV-1)
RNA levels in patients with advanced HIV-1 disease and with
little or no prior zidovudine therapy. J Infect Dis 1996;174:696.
142. Coombs RW, Welles SL, Hooper C, et al. Association of plasma
human immunodeficiency virus type 1 RNA level with risk of
clinical progression in patients with advanced HIV infection.
J Infect Dis 1996;174:704.
143. OBrien WA, Hartigan PM, Martin D, et al. Changes in plasma
HIV-1 RNA and CD4+ lymphocyte counts and the risk of
progression to AIDS. N Engl J Med 1996;334:425.
144. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation
of virologic and immunologic markers to clinical outcomes
after nucleoside therapy in HIV-infected adults with 200 to 500
CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091.
145. Marschner IC, Collier AC, Coombs RW, et al. Use of changes
in plasma levels of human immunodeficiency virus type-1
RNA to assess the clinical benefit of antiretroviral therapy. J
Infect Dis 1998;177:40.
146. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and
heterosexual transmission of human immunodeficiency virus
type 1. N Engl J Med 2000;342:921.
147. Jacquez J, Koopman J, Simon C, et al. Role of the primary
infection in epidemics of HIV infection in gay cohorts. J Acquir
Immune Defic Syndr 1994;7:1169.
148. Rich JD, Merriman NA, Mylonakis E, et al. Misdiagnosis of
HIV infection by HIV-1 plasma viral load testing: a case series.
Ann Intern Med 1999;130:37.
Principles of Medicine
149. Musey L, Hughes J, Schacker T, et al. Cytotoxic-T-cell responses,
viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997;337:1267.
150. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous
HIV-1-specific CD4+ T-cell responses associated with control
of viremia. Science 1997;278:1447.
151. Daar ES, Little SJ, Pitt JA, et al. Protease inhibitor (PI)- and
non-PI-containing antiretroviral therapy (ART) compared to
no treatment in primary HIV infection (PHI) [abstract402].
Program and abstracts of the 8th Conference on Retroviruses
and Opportunistic Infections; 2001 Feb 48; Chicago, Illinois.
152. Lifson AR, Rutherford TW, Jaffe HW. The natural history of
human immunodeficiency virus infection. J Infect Dis
1988;158:1360.
153. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of
human immunodeficiency virus-associated opportunistic
infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30:S5.
154. Michelet C, Arvieux C, Franois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment.
AIDS 1998;12:1815.
155. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of
the correlates of protective immunity to HIV infection. Science
1996;271:324.
156. Dean M, Carrington M, Winkler C, et al. Genetic restriction of
HIV-1 infection and progression to AIDS by a deletion allele
of the CKR5 structural gene. Hemophilia Growth and
Development Study, Multicenter AIDS Cohort Study,
Multicenter Hemophilia Cohort Study, San Francisco City
Cohort, ALIVE Study. Science 1996;273:1856.
157. Horuk R. Chemokine receptors and HIV-1: the fusion of two
major research fields. Immunol Today 1999;20:89.
158. McDermott DH, Zimmerman PA, Guignard F, et al. CCR5
promoter polymorphism and HIV-1 disease progression.
Lancet 1998;352:866.
159. Levy JA, Mackewicz CE, Barker E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8(+)
T cells. Immunol Today 1996;17:217.
160. Richman DD, Bozzette SA. The impact of the syncytiuminducing phenotype of human immunodeficiency virus on
disease progression. J Infect Dis 1994;169:968.
161. Berger EA, Murphy PM, Farber JM. Chemokine receptors as
HIV-1 coreceptors: roles in viral entry, tropism, and disease.
Ann Rev Immunol 1999;17:657.
162. Learmont J, Geczy A, Raynes-Greenow C, et al. The Sydney
Blood Bank Cohort infected with attenuated quasispecies of
HIV-1: long-term nonprogression [abstract 13350]. XII World
AIDS Conference; 1998 June 28July 3;Geneva, Switzerland.
163. Klein MR, VanBaalen CA, Holwerden AM, et al. Kinetics of
Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid
progressors and long-term asymptomatics. J Exp Med
1995;181:1365.
164. Glick M. Dental management of patients with HIV. Carol
Stream (IL): Quintessence Publishing Co, Inc.; 1994.
165. Abel SN, Croser D, Fischman SL, et al. Dental Alliance for
AIDS/HIV Care (DAAC): principles of dental management
for the HIV-infected patient. Dental Alliance for AIDS/HIV
Care; 1999.
166. Patton LL, Glick M. Clinicians guide to treatment of HIVinfected patients. 3rd ed. American Academy of Oral
Medicine; 2001.
Infectious Diseases
167. Glick M, Abel S. Dental implants and HIV disease. Implant
Dent 1993;2:149.
168. Dodson TB, Perrott DH, Gongloff RK, et al. Human immunodeficiency virus serostatus and the risk of postextraction
complications. Int J Maxillofac Surg 1994;2:100.
169. Glick M, Abel S, Muzyka B, et al. Dental complications after
treating patients with AIDS. J Am Dent Assoc 1994;125:296.
170. Patton LL, Shugars DC. Immunologic and viral markers of
HIV-1 disease progression: implications for dentistry. J Am
Dent Assoc 1999;130:1313.
171. Glick M. Intravenous drug users: a consideration for infective
endocarditis in dentistry? [editorial] Oral Surg Oral Med Oral
Pathol Oral Radiol Endod 1995;80:125.
172. Glick M, Muzyka BC, Lurie D, et al. Oral manifestations associated with HIV disease as markers for immune suppression
and AIDS. Oral Surg Oral Med Oral Pathol 1994;77:344.
173. Glick M, Muzyka BC, Salkin LM, et al. Necrotizing ulcerative
periodontitis: a marker for immune deterioration and a predictor for the diagnosis of AIDS. J Periodontol 1994;65:393.
174. Patton LL. Sensitivity, specificity, and positive predictive value
of oral opportunistic infections in adults with HIV/AIDS as
markers of immune suppression and viral burden. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod 2000;90:182.
175. Glick M, Berthold P. Oral manifestations and conditions found
in individuals with HIV infection. In: Buckley RM, editor. HIV
infection in primary care. Philadelphia (PA): W. B. Saunders;
[In press]
176. Muzyka BC, Glick M. A review of oral fungal infections and
appropriate therapy. J Am Dent Assoc 1995;126:63.
177. Patton LL, McKaig R, Strauss R, et al. Changing prevalence of
oral manifestations of human immunodeficiency virus in the
era of protease inhibitor therapy. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod 2000;89:299.
178. Barr CE, Glick M. Diagnosis and management of oral and
cutaneous lesions in HIV-1 disease. Oral Maxillofac Surg Clin
North Am 1998;1:25.
179. Kademani D, Glick M. Oral ulcerations in individuals infected
with human immunodeficiency virus: clinical presentations,
diagnosis, management, and relevance to disease progression.
Quintessence Int 1998;29:523.
180. Ghannoum MA, Elewski B. Successful treatment of fluconazole resistant oropharyngeal candidiasis by a combination of
fluconazole and terbinafine. Clin Diagn Lab Immunol
1999;6:921.
181. Diz Dios P, Ocampo A, Miralles C, et al. Frequency of oropharyngeal candidiasis in HIV-infected patients on protease
inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod 1999:87;437.
182. Glick M, Cohen SG, Cheney RT, et al. Oral manifestations of
disseminated Cryptococcus in a patient with acquired immunodeficiency syndrome. Oral Surg Oral Med Oral Pathol
1987;64:454.
183. Heinic GS, Greenspan D, MacPhail LA, et al. Oral Geotrichum
candidum infection associated with HIV infection. A case
report. Oral Surg Oral Med Oral Pathol 1992;73:7268.
184. MacPhail LA, Greenspan D, Shiodt M, et al. Acyclovir-resistant,
foscarnet-sensitive oral herpes simplex type 2 lesion in a patient
with AIDS. Oral Surg Oral Med Oral Pathol 1989;67:427.
185. Heinic GS, Northfelt DW, Greenspan JS, et al. Concurrent oral
CMV and HSV infection in association with HIV infection: a
case report. Oral Surg Oral Med Oral Pathol 1993;75:488.
561
186. Glick M, Cleveland DB, Salkin LM, et al. Intraoral
Cytomegalovirus lesion and HIV-associated periodontitis in a
patient with acquired immunodeficiency syndrome. Oral Surg
Oral Med Oral Pathol 1991;72:716.
187. Kabani S, Greenspan D, deSouze Y, et al. Oral hairy leukoplakia with extensive oral mucosal involvement. Oral Surg
Oral Med Oral Pathol 1989;67:411.
188. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency
virus. Clin Infect Dis 1995;21:370.
189. Breton G, Fillet AM, Katlama C, et al. Acyclovir-resistant herpes zoster in human immunodeficiency virusinfected
patients: results of foscarnet study. Clin Infect Dis
1998;27:1525.
190. Martinez E, Gatell J, MoranY, et al. High incidence of herpes
zoster in patients with AIDS soon after protease inhibitor therapy. Clin Infect Dis 1998;27:1510.
191. Ensoli B, Sgadari C, Barillari G, et al. Biology of Kaposis sarcoma. Eur J Cancer 2001;1251.
192. Glick M, Cleveland DB. Oral mucosal bacillary (epithelioid)
angiomatosis in a patient with AIDS-associated with rapid
alveolar bone loss: a case report. J Oral Pathol Med 1993;
22:235.
193. Muzyka BC, Glick M. Sclerotherapy for the treatment of nodular intraoral Kaposis sarcoma in patients with AIDS [correspondence]. N Engl J Med 1993;328:210.
194. Yarchoan R. Therapy for Kaposis sarcoma: recent advances
and experimental approaches. J AIDS 1999;21:S66.
195. Itin PH, Latenschlager S. Viral lesions of the mouth in HIVinfected patients. Dermotology 1997;194:1.
196. Lozada-Nur F, Glick M, Shubert M, et al. Use of intralesional
interferon-alpha for the treatment of recalcitrant oral warts in
patients with AIDS: report of 4 cases. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. [In press]
197. Lamster IB, Grbic JT, Mitchell-Lewis D, et al. New concepts
regarding the pathogenesis of periodontal disease in HIV
infection. Ann Periodontol 1998;3:62.
198. Dimitrakopolous I, Zouloumis L, Lazaridis N, et al. Primary
tuberculosis of the oral cavity. Oral Surg Oral Med Oral Pathol
1991;72:712.
199. Eng HL, Lu SY, Yang CH, et al. Oral tuberculosis. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod 1996;81:415.
200. Ficarra G, Zaragoza AM, Stendardi L, et al. Early oral presentation of lues maligna in a patient with HIV infection. Oral
Surg Oral Med Oral Pathol 1993;75:728.
201. Muzyka BC, Glick M. Necrotizing stomatitis and AIDS. Gen
Dent 1994;42:66.
202. Muzyka BC, Glick M. Major aphthous ulceration in patients
with HIV disease. Oral Surg Oral Med Oral Pathol 1994;77:116.
203. Glick M, Muzyka BC. Alternative therapies for major aphthous
ulcers in AIDS patients. J Am Dent Assoc 1992;123:61.
204. Gilquin J, Weiss L, Kazatchkine MD. Genital and oral erosions
induced by foscarnet. Lancet 1990;335:287.
205. McLeod GX, Hammer SM. Zidovudine: five years later. Ann
Intern Med 1992;117:487.
206. McNeely MC, Yarchoan R, Broder S, et al. Dermatologic complications associated with administration of 23-dideoxycytidine in patients with human immunodeficiency virus. J Am
Acad Dermatol 1989;21:1213.
207. Shiodt M. Less common oral lesions associated with HIV
infection: prevalence and classification. Oral Dis 1997;3:S208.
562
208. Luzzi GA, Jones BJ. Treatment of neutropenic oral ulceration
in human immunodeficiency virus infection with G-CSF. Oral
Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81:53.
209. Greenberg MS, Glick M, Nghiem L, et al. Relationship of
Cytomegalovirus to salivary gland dysfunction in HIV-infected
patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
1997;83:334.
210. Flaitz CM, Hicks MJ. Oral candidiasis in children with immune
suppression: clinical appearance and therapeutic considerations. ASDC J Dent Child 1999;66:161.
Principles of Medicine
211. Nicolatou O, Theodoridou M, Mostrou G, et al. Oral lesions in
children with perinatally acquired human immunodeficiency
virus infection. J Oral Pathol Med 1999;28:49.
212. Velegraki A, Nicolatou O, Theodoridou M, et al. Paediatric
AIDS-related linear gingival erythema: a form of erythematous
candidiasis? J Oral Pathol Med 1999;28:178.
213. Flynn PM, Cunningham CK, Kerkering T, et al. Oropharyngeal
candidiasis in immunocompromised children: a randomized,
multicenter study of orally administered fluconazole suspension versus nystatin. J Pediatr 1995;127;322.